Logo image of DNTH

DIANTHUS THERAPEUTICS INC (DNTH) Stock Fundamental Analysis

NASDAQ:DNTH - Nasdaq - US2528281080 - Common Stock - Currency: USD

24.03  +0.51 (+2.17%)

After market: 24.03 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to DNTH. DNTH was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for DNTH as it has an excellent financial health rating, but there are worries on the profitability. DNTH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DNTH had negative earnings in the past year.
DNTH had a negative operating cash flow in the past year.
DNTH had negative earnings in each of the past 5 years.
In the past 5 years DNTH always reported negative operating cash flow.
DNTH Yearly Net Income VS EBIT VS OCF VS FCFDNTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -18.94%, DNTH is in the better half of the industry, outperforming 79.90% of the companies in the same industry.
Looking at the Return On Equity, with a value of -19.86%, DNTH belongs to the top of the industry, outperforming 86.71% of the companies in the same industry.
Industry RankSector Rank
ROA -18.94%
ROE -19.86%
ROIC N/A
ROA(3y)-37.96%
ROA(5y)-41.56%
ROE(3y)-46.37%
ROE(5y)-49.11%
ROIC(3y)N/A
ROIC(5y)N/A
DNTH Yearly ROA, ROE, ROICDNTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

DNTH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNTH Yearly Profit, Operating, Gross MarginsDNTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

DNTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DNTH has been increased compared to 1 year ago.
Compared to 5 years ago, DNTH has more shares outstanding
There is no outstanding debt for DNTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DNTH Yearly Shares OutstandingDNTH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
DNTH Yearly Total Debt VS Total AssetsDNTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

DNTH has an Altman-Z score of 25.69. This indicates that DNTH is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 25.69, DNTH belongs to the best of the industry, outperforming 95.28% of the companies in the same industry.
DNTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 25.69
ROIC/WACCN/A
WACC10.57%
DNTH Yearly LT Debt VS Equity VS FCFDNTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 18.30 indicates that DNTH has no problem at all paying its short term obligations.
DNTH has a Current ratio of 18.30. This is amongst the best in the industry. DNTH outperforms 93.53% of its industry peers.
A Quick Ratio of 18.30 indicates that DNTH has no problem at all paying its short term obligations.
DNTH has a better Quick ratio (18.30) than 93.53% of its industry peers.
Industry RankSector Rank
Current Ratio 18.3
Quick Ratio 18.3
DNTH Yearly Current Assets VS Current LiabilitesDNTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.88% over the past year.
The Revenue has grown by 126.41% in the past year. This is a very strong growth!
EPS 1Y (TTM)85.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.42%
Revenue 1Y (TTM)126.41%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%135.06%

3.2 Future

DNTH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.81% yearly.
DNTH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 85.03% yearly.
EPS Next Y79.85%
EPS Next 2Y31.47%
EPS Next 3Y19.34%
EPS Next 5Y11.81%
Revenue Next Year139.46%
Revenue Next 2Y26.59%
Revenue Next 3Y15.77%
Revenue Next 5Y85.03%

3.3 Evolution

DNTH Yearly Revenue VS EstimatesDNTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 2032 200M 400M 600M 800M
DNTH Yearly EPS VS EstimatesDNTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DNTH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNTH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNTH Price Earnings VS Forward Price EarningsDNTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNTH Per share dataDNTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

DNTH's earnings are expected to grow with 19.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.47%
EPS Next 3Y19.34%

More info and screens

0

5. Dividend

5.1 Amount

DNTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIANTHUS THERAPEUTICS INC

NASDAQ:DNTH (3/7/2025, 8:20:07 PM)

After market: 24.03 0 (0%)

24.03

+0.51 (+2.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-20 2025-03-20/amc
Inst Owners119.34%
Inst Owner Change12.13%
Ins Owners0.02%
Ins Owner Change0%
Market Cap711.29M
Analysts87.78
Price Target53.65 (123.26%)
Short Float %19.67%
Short Ratio22.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.85%
Min EPS beat(2)-22.05%
Max EPS beat(2)8.35%
EPS beat(4)2
Avg EPS beat(4)-0.87%
Min EPS beat(4)-22.05%
Max EPS beat(4)31.08%
EPS beat(8)3
Avg EPS beat(8)-66.16%
EPS beat(12)5
Avg EPS beat(12)-43.87%
EPS beat(16)9
Avg EPS beat(16)-29.78%
Revenue beat(2)2
Avg Revenue beat(2)347.13%
Min Revenue beat(2)228.36%
Max Revenue beat(2)465.91%
Revenue beat(4)4
Avg Revenue beat(4)206.31%
Min Revenue beat(4)46.42%
Max Revenue beat(4)465.91%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.52%
EPS NY rev (1m)0%
EPS NY rev (3m)0.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.16%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 132.55
P/FCF N/A
P/OCF N/A
P/B 2.11
P/tB 2.11
EV/EBITDA N/A
EPS(TTM)-2.5
EYN/A
EPS(NY)-3.52
Fwd EYN/A
FCF(TTM)-2.12
FCFYN/A
OCF(TTM)-2.11
OCFYN/A
SpS0.18
BVpS11.42
TBVpS11.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.94%
ROE -19.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.96%
ROA(5y)-41.56%
ROE(3y)-46.37%
ROE(5y)-49.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.55%
Cap/Sales 1.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.3
Quick Ratio 18.3
Altman-Z 25.69
F-Score6
WACC10.57%
ROIC/WACCN/A
Cap/Depr(3y)80.87%
Cap/Depr(5y)85.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.42%
EPS Next Y79.85%
EPS Next 2Y31.47%
EPS Next 3Y19.34%
EPS Next 5Y11.81%
Revenue 1Y (TTM)126.41%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%135.06%
Revenue Next Year139.46%
Revenue Next 2Y26.59%
Revenue Next 3Y15.77%
Revenue Next 5Y85.03%
EBIT growth 1Y-112.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y5.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.3%
OCF growth 3YN/A
OCF growth 5YN/A